{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:35:01Z","timestamp":1791819301525,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.phrs.2016.10.019","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T17:20:45Z","timestamp":1477070445000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo"],"prefix":"10.1016","volume":"114","author":[{"given":"Paola","family":"De Cicco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ercolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Armogida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pirozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Cirino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ianaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.10.019_bib0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Coussens","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.10.019_bib0010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.10.019_bib0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10555-010-9228-1","article-title":"Role of inflammatory cells and mediators in tumor invasion and metastasis","volume":"29","author":"Mantovani","year":"2010","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.phrs.2016.10.019_bib0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2016.10.019_bib0025","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.10.019_bib0030","first-page":"1742","article-title":"Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids","volume":"60","author":"Cahlin","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2016.10.019_bib0035","first-page":"303","article-title":"Expression of cyclooxygenase 2 in human malignant melanoma","volume":"61","author":"Denkert","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2016.10.019_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.cmr.0000194430.77643.a0","article-title":"Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression","volume":"16","author":"Kuzbicki","year":"2006","journal-title":"Melanoma Res."},{"key":"10.1016\/j.phrs.2016.10.019_bib0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrd4433","article-title":"Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter","volume":"14","author":"Wallace","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.10.019_bib0050","doi-asserted-by":"crossref","first-page":"G467","DOI":"10.1152\/ajpgi.00169.2013","article-title":"Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments","volume":"305","author":"Chan","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.phrs.2016.10.019_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/pcmr.12312","article-title":"Role of the cystathionine gamma lyase\/hydrogen sulfide pathway in human melanoma progression","volume":"28","author":"Panza","year":"2015","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.phrs.2016.10.019_bib0060","doi-asserted-by":"crossref","first-page":"e21077","DOI":"10.1371\/journal.pone.0021077","article-title":"The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.10.019_bib0065","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bcp.2011.12.019","article-title":"Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo","volume":"83","author":"Chattopadhyay","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2016.10.019_bib0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tips.2007.09.003","article-title":"Hydrogen sulfide-releasing anti-inflammatory drugs","volume":"28","author":"Wallace","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2016.10.019_bib0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.canlet.2008.09.038","article-title":"NEMO-binding domain peptide inhibits proliferation of human melanoma cells","volume":"274","author":"Ianaro","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2016.10.019_bib0080","first-page":"3157","article-title":"Development of a new melanoma model in C57BL\/6 mice","volume":"42","author":"Berkelhammer","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2016.10.019_bib0085","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1600-0749.2006.00304.x","article-title":"NF-kappaB activation in melanoma","volume":"19","author":"Ueda","year":"2006","journal-title":"Pigm. Cell Res."},{"key":"10.1016\/j.phrs.2016.10.019_bib0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.10.019_bib0095","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.10.019_bib0100","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1074\/jbc.M007806200","article-title":"Tumor suppressor MMAC\/PTEN inhibits cytokine-induced NFkappaB activation without interfering with the IkappaB degradation pathway","volume":"276","author":"Koul","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.10.019_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1189\/jlb.72.1.9","article-title":"Role of CXCL1 in tumorigenesis of melanoma","volume":"72","author":"Dhawan","year":"2002","journal-title":"J. Leukoc. Biol."},{"issue":"2016","key":"10.1016\/j.phrs.2016.10.019_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics","volume":"66","author":"Siegel","year":"2016","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.phrs.2016.10.019_bib0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1476-5381.2009.00611.x","article-title":"Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346)","volume":"159","author":"Wallace","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.10.019_bib0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.niox.2014.04.006","article-title":"Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer","volume":"41","author":"Elsheikh","year":"2014","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.phrs.2016.10.019_bib0125","doi-asserted-by":"crossref","first-page":"e0147289","DOI":"10.1371\/journal.pone.0147289","article-title":"Profound chemopreventative effects of a hydrogen sulfide-releasing NSAID in the APCMin\/+ mouse model of intestinal tumorigenesis","volume":"11","author":"Paul-Clark","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.10.019_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/0471142905.hg1011s57","article-title":"The catalogue of somatic mutations in cancer (COSMIC)","author":"Forbes","year":"2008","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"10.1016\/j.phrs.2016.10.019_bib0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-0560.2006.00675.x","article-title":"Expression of activated Akt in benign nevi, Spitz nevi and melanomas","volume":"34","author":"Kantrow","year":"2007","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.phrs.2016.10.019_bib0140","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/onc.2011.160","article-title":"Raf kinases in cancer-roles and therapeutic opportunities","volume":"30","author":"Maurer","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2016.10.019_bib0145","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1074\/jbc.M312044200","article-title":"Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP)","volume":"279","author":"Dan","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.10.019_bib0150","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816305199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816305199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T15:23:22Z","timestamp":1692545002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816305199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":30,"alternative-id":["S1043661816305199"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.10.019","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}